Comparative Efficacy of Myostatin Inhibitors vs. Traditional Anabolics

Two Different Ways to Flip the Growth Switch

Building muscle beyond your genetic potential means overriding the body's push toward homeostasis. For decades, the only reliable way to do that was with traditional anabolics: hitting the gas pedal with androgens.

Anabolic-androgenic steroids (AAS) work by directly activating the androgen receptor (AR). Think of it as a brute-force approach. Androgens bind to ARs in muscle cells, and this directly kickstarts the machinery for protein synthesis. More testosterone, more AR activation, more muscle. It's a fairly linear and relatively well-understood process.

Myostatin inhibitors work differently. They don't touch the androgen receptor. Instead, they work by cutting the brakes. Your body produces a protein called myostatin to limit how much muscle you build. It's a negative regulator. Myostatin inhibitors, like follistatin or the discontinued experimental drug ACE-031, work by binding to myostatin (or blocking its receptor) and preventing it from doing its job. By removing this handbrake, you allow your muscles to grow past their normal set point. It's a clever, indirect approach, and it's why researchers and lifters got so excited about it.

Pound for Pound, Which Builds More Muscle?

This is the question most lifters care about. If you're going to accept the risks, you want the results. And right now, it's not a fair fight.

For sheer, quantifiable mass gain, traditional anabolics are still well ahead. The best-known controlled trial, published in the New England Journal of Medicine in 1996, gave 43 healthy men 600 mg of testosterone enanthate or placebo weekly for 10 weeks. The men who got testosterone and lifted weights gained about 6.1 kg of fat-free mass, and even the testosterone group that didn't train got bigger and stronger than placebo. Community cycle reports describe higher doses and stacks of several compounds, which no trial has tested, but the pattern holds: the results are dose-dependent and substantial. Part of the scale weight is contractile tissue, and part is water and glycogen.

Myostatin inhibitors are a different story. The famous animal data (Belgian Blue cattle and the heavily muscled "mighty mice"), plus a 2004 NEJM report of a boy born with a myostatin mutation and unusually large muscles, created an expectation that hasn't carried over to drugs given to adults. The human evidence has grown, though:

• ACE-031 in boys with Duchenne muscular dystrophy. In the randomized, placebo-controlled trial (published in Muscle & Nerve in 2017), the boys showed only a trend toward more lean mass and bone density and less fat. The study was stopped early in 2011 over safety concerns, and the developers dropped the drug in 2013 (more in our ACE-031 overview).
• Bimagrumab in adults with obesity. In the BELIEVE Phase 2 trial (507 adults, Nature Medicine, 2026), bimagrumab alone, given at 10 or 30 mg/kg IV every 12 weeks, raised lean mass by only about 1% at 48 weeks, and by 2.5% at 72 weeks at the higher dose. Added to semaglutide, it cut lean-mass loss from 4.7-6.9% to 0.8-2.3% at 48 weeks. Grip strength and patient-reported function didn't improve significantly.
• Trevogrumab with semaglutide. In Regeneron's COURAGE Phase 2 trial, reported in October 2026, 75 mg of trevogrumab plus semaglutide held lean-mass loss at 52 weeks to 4.2%, versus 7.3% on semaglutide alone. It didn't add any weight loss.
• Apitegromab in spinal muscular atrophy. As of October 2026, it's the only approved myostatin-targeted drug. The FDA approved it (as Isembyld) in September 2026 for SMA in patients 2 and older who already take an SMN2-targeted therapy, based on better motor-function scores. It's approved for that disease, not for building muscle.

So these drugs do act on human muscle, but the measured effects are about preserving muscle or adding a few percent, not the growth seen in knockout animals. Anecdotal reports from bodybuilders using research-grade follistatin often describe a change in muscle quality (more hardness, fullness, and a "denser" look) but rarely the large scale-weight increases users report from an AAS cycle. No human study has tested those gray-market products, and what's in the vials is unverified (see our follistatin page).

Part of the gap is timing. Animals bred with no myostatin gene from birth are different from an adult human temporarily suppressing it. We aren't starting from the same place. For now, if your only goal is maximum mass, AAS are the more effective tool by a wide margin.

The Mechanism Matters: A Look at Gains and Risks

How much muscle you build is only part of the comparison; how you build it and what price you pay matter too. The mechanisms behind AAS and myostatin inhibitors lead to very different outcomes and side effect profiles.

Anabolics build muscle primarily through hypertrophy, making existing muscle fibers bigger. The side effects are androgenic and estrogenic. The list is well known: shutdown of the body's own testosterone production (HPTA shutdown), higher blood pressure, worse lipid profiles, liver strain from oral steroids, and estrogen-related effects. It's a long list, but it's a known list. Clinicians and users have ways to monitor and reduce (not eliminate) these risks, built up over decades.

Myostatin inhibitors are where things get less predictable. The upside people often cite is hyperplasia, the creation of new muscle fibers rather than growth of existing ones, which many bodybuilders see as the ideal. The animal research is narrower than that: myostatin sets the number of fibers during embryonic development, while in adults it mainly limits how large existing fibers grow. So extra fibers in knockout animals don't mean an adult would gain new fibers from a drug. And myostatin (and the receptor it acts on, ActRIIB) works outside muscle too. Its pathway is involved in signaling all over the body.

That's what halted the ACE-031 trial. It wasn't for lack of efficacy. ACE-031 is a decoy receptor that binds myostatin and related proteins, and some participants developed minor nose and gum bleeding and small, dilated blood vessels (telangiectasias) in the skin. These cleared up after treatment stopped, but regulators wanted them understood first, and later animal toxicology studies didn't support restarting. This suggests the drug was having off-target effects on vascular tissue. You're not only cutting the brakes on muscle; you might be affecting other systems as well.

Newer drugs are more selective antibodies, and their safety record is mixed. As of October 2026, apitegromab's FDA label warns of an increased risk of fractures, including serious ones. In BELIEVE, bimagrumab caused muscle spasms, diarrhea and acne, and more people stopped it because of side effects than stopped semaglutide. In COURAGE, two participants on a triple combination of high-dose trevogrumab, the activin A antibody garetosmab and semaglutide died, and Regeneron dropped that combination. None of these drugs has long-term data in healthy, training adults.

Head-to-Head Comparison

The Synergy Argument

Experienced AAS users often ask about combining the two. If one presses the gas and the other cuts the brakes, the reasoning goes, using both should produce bigger results than either alone.

On paper, the logic holds up. Since they operate on largely independent pathways, the effects could be additive or more. You're stimulating growth from one end while removing the primary stop signal from the other. Nobody has tested the combination in people. The closest example is the SARM YK-11: in a 2013 cell-culture study, it acted as a partial AR agonist and raised follistatin in mouse muscle cells, and blocking follistatin cancelled its effect. That's one cell study, not evidence that it works this way in people. WADA lists YK-11 with the other anabolic agents under S1.2.

But stacking these means stacking two different categories of risk. You're taking the known cardiovascular and endocrine risks of AAS and layering on the poorly understood systemic risks of myostatin inhibition. Nobody knows what long-term myostatin suppression does to the heart, which also makes myostatin in rat studies, or to tendons and ligaments (see long-term effects of myostatin inhibition). Combining a known risk with an unknown one doesn't give you a calculated risk; it gives you a gamble.

Where the Comparison Stands

Anabolic steroids, for all their faults, are the predictable tool here. They work. The risks are serious, but decades of research and use have made them largely a known quantity.

Myostatin and activin blockers are no longer only a lab curiosity. As of October 2026, one is approved for SMA, and two antibodies have protected lean mass during semaglutide weight loss in Phase 2 trials. Building muscle through a non-androgenic pathway is still an attractive idea. But the human data measure muscle preservation in patients, not growth in trained athletes, and the side effects that stopped ACE-031 were systemic and vascular. The research-grade follistatin and "ACE-031" sold online have no human data behind them at all.

If you're a bodybuilder operating at the extreme end, myostatin inhibitors might seem like the next frontier. But for most lifters, they are a high-risk, unproven variable, and they're prohibited in tested sport. Right now, between flooring the gas and cutting the brakes, the gas pedal is still the more reliable and better understood way to add muscle.

What to Watch Next

• As of October 2026, Regeneron plans a Phase 2 trial of trevogrumab with GLP-1 drugs in older adults with obesity and low muscle mass or strength.
• A Phase 2 trial is testing bimagrumab given subcutaneously with tirzepatide (NCT06643728).
• Whether preserved lean mass turns into better strength or function. BELIEVE found no significant improvement in grip strength.